Eleven people have been killed in a nine-nation, 24-week clinical trial sponsored by Japan’s Eisai. The drug, Aricept, is for Alzheimer’s disease and is co-marketed with Pfizer.  The clinical trial was testing Aricept in patients with dementia traced to vascular problems. The drug is not approved for that indication in the U.S. No patients receiving the placebo died—a surprise given the underlying level of heart disease in all of the patients in the trial.